UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Increasing burden of liver disease in patients with HIV infection

The Lancet (British edition), 2011-04, Vol.377 (9772), p.1198-1209

2011

Volltextzugriff (PDF)

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection

Journal of hepatology, 2015-03, Vol.62 (3), p.533-540

2015

Volltextzugriff (PDF)

THU-235 Bridging hepatic pathologies: protein expression dynamics in metabolic dysfunction-associated liver disease (MASLD), benign liver tumours and hepatocellular carcinoma

Journal of hepatology, 2024-06, Vol.80, p.S577-S577

2024

Volltextzugriff (PDF)

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Journal of hepatology, 2017-08, Vol.67 (2), p.370-398

2017

Volltextzugriff (PDF)

Antiviral treatment in patients with advanced hepatitis C virus cirrhosis with sofosbuvir and either ledipasvir or daclatasvir, with or without ribavirin: observational cohort study

The Lancet (British edition), 2016-02, Vol.387, p.S26-S26

2016

Volltextzugriff (PDF)

Antisense oligonucleotides (ASOs) in chronic hepatitis B infection: Opportunities and challenging the orthodoxy

Journal of hepatology, 2022-10, Vol.77 (4), p.906-908

2022

Volltextzugriff (PDF)

FRI-410 Mitochondrial dysfunction and metabolic plasticity in the hepatitis B virus specific immune response: new insights and implications for hepatitis B virus cure

Journal of hepatology, 2024-06, Vol.80, p.S780-S780

2024

Volltextzugriff (PDF)

A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV ‘cure’

Journal of hepatology, 2022-07, Vol.77 (1), p.245-248

2022

Volltextzugriff (PDF)

Development and validation of an efficient in-house real-time reverse transcription polymerase chain reaction assay for the quantitative detection of serum hepatitis delta virus RNA in a diverse South London population

Journal of virological methods, 2012-09, Vol.184 (1-2), p.55-62

2012

Volltextzugriff (PDF)

Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1

Journal of hepatology, 2020-06, Vol.72 (6), p.1097-1104

2020

Volltextzugriff (PDF)

EASL Clinical Practice Guidelines on hepatitis delta virus

Journal of hepatology, 2023-08, Vol.79 (2), p.433-460

2023

Volltextzugriff (PDF)

Lack of awareness of a NAFLD pandemic in a high risk group. Is it time to act in primary care?

Journal of hepatology, 2022-07, Vol.77, p.S171

2022

Volltextzugriff (PDF)

The serum markers of cccDNA transcriptional activity have a role in predicting long-term outcomes in children with perinatally acquired HBV infection

Journal of hepatology, 2022-07, Vol.77, p.S287

2022

Volltextzugriff (PDF)

Validation of an internal hepatitis D virus DNA quantitative assay: developing assay suitable for global clinical application and clinical trials assessment

Journal of hepatology, 2022-07, Vol.77, p.S280

2022

Volltextzugriff (PDF)

Predictive performance of hepatocellular carcinoma risk scores in chronic hepatitis C patients with advanced fibrosis after achieving sustained virological response: Insights from European Association for the study of the Liver Policy recommendations

European journal of internal medicine, 2024-11, Vol.129, p.155-157

2024

Volltextzugriff (PDF)

Overview of New Targets for Hepatitis B Virus

Clinics in liver disease, 2023-11, Vol.27 (4), p.857-876

2023

Volltextzugriff (PDF)

FRI-399 Hepatitis B core-related antigen is a good predictor for high risk of mother to child transmission in chronic hepatitis B

Journal of hepatology, 2024-06, Vol.80, p.S775-S775

2024

Volltextzugriff (PDF)

Hepatitis A and E and other hepatotropic viruses

Medicine (Abingdon. 1995, UK ed.), 2023-05, Vol.51 (5), p.347-350

2023

Volltextzugriff (PDF)

Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C

Journal of hepatology, 2019-12, Vol.71 (6), p.1099-1105

2019

Volltextzugriff (PDF)

WED-143 - Novel serum markers of cccDNA transcriptional activity-HBcrAg and pre-genomic RNA and CXCL10 pro-inflammatory chemokine levels can reduce uncertainty of HBeAg-negative chronic hepatitis B phases

Journal of hepatology, 2023-06, Vol.78, p.S1081-S1081

2023

Volltextzugriff (PDF)

Novel serum markers of cccDNA transcriptional activity-HBcrAg and pre-genomic RNA and CXCL10 pro-inflammatory chemokine levels can reduce uncertainty of HBeAg-negative chronic hepatitis B phases

Journal of hepatology, 2023-06, Vol.78, p.S1081

2023

Volltextzugriff (PDF)

HDV genotypes have an impact on pegylated interferon therapy response and long-term liver disease related outcomes

Journal of hepatology, 2023-06, Vol.78, p.S1081-S1082

2023

Volltextzugriff (PDF)

WED-144 - HDV genotypes have an impact on pegylated interferon therapy response and long-term liver disease related outcomes

Journal of hepatology, 2023-06, Vol.78, p.S1081-S1082

2023

Volltextzugriff (PDF)

The rising burden of non-alcoholic fatty liver disease (NAFLD) related HCC: is time running out to contain this silent epidemic?

Journal of hepatology, 2023-06, Vol.78, p.S642

2023

Volltextzugriff (PDF)

1 – 25 von 197

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Viral Hepatitis

KollektionElsevier ScienceDirect Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(197)
Mit Volltextzugriff
(194)

Publikationsform

Artikel
(196)
Tagungsberichte
(1)

Sprache

Englisch
(197)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(49)
Science & Technology
(49)
Gastroenterology & Hepatology
(39)
Humans
(37)
Gastroenterology And Hepatology
(25)
Male
(20)
Female
(19)
Middle Aged
(19)
Antiviral Agents - Therapeutic Use
(16)
Patients
(16)
Adult
(14)
Hepatitis
(14)
Hepatitis C, Chronic - Drug Therapy
(13)
Hepatitis C
(11)
Liver Cirrhosis
(11)
Treatment Outcome
(11)
Antiviral Agents
(10)
Genotype
(10)
Hepacivirus - Genetics
(10)
Genotypes
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Increasing burden of liver disease in patients with HIV infection

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection

THU-235 Bridging hepatic pathologies: protein expression dynamics in metabolic dysfunction-associated liver disease (MASLD), benign liver tumours and hepatocellular carcinoma

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Antiviral treatment in patients with advanced hepatitis C virus cirrhosis with sofosbuvir and either ledipasvir or daclatasvir, with or without ribavirin: observational cohort study

Antisense oligonucleotides (ASOs) in chronic hepatitis B infection: Opportunities and challenging the orthodoxy

FRI-410 Mitochondrial dysfunction and metabolic plasticity in the hepatitis B virus specific immune response: new insights and implications for hepatitis B virus cure

A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV ‘cure’

Development and validation of an efficient in-house real-time reverse transcription polymerase chain reaction assay for the quantitative detection of serum hepatitis delta virus RNA in a diverse South London population

Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1

EASL Clinical Practice Guidelines on hepatitis delta virus

Lack of awareness of a NAFLD pandemic in a high risk group. Is it time to act in primary care?

The serum markers of cccDNA transcriptional activity have a role in predicting long-term outcomes in children with perinatally acquired HBV infection

Validation of an internal hepatitis D virus DNA quantitative assay: developing assay suitable for global clinical application and clinical trials assessment

Predictive performance of hepatocellular carcinoma risk scores in chronic hepatitis C patients with advanced fibrosis after achieving sustained virological response: Insights from European Association for the study of the Liver Policy recommendations

Overview of New Targets for Hepatitis B Virus

FRI-399 Hepatitis B core-related antigen is a good predictor for high risk of mother to child transmission in chronic hepatitis B

Hepatitis A and E and other hepatotropic viruses

Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C

WED-143 - Novel serum markers of cccDNA transcriptional activity-HBcrAg and pre-genomic RNA and CXCL10 pro-inflammatory chemokine levels can reduce uncertainty of HBeAg-negative chronic hepatitis B phases

Novel serum markers of cccDNA transcriptional activity-HBcrAg and pre-genomic RNA and CXCL10 pro-inflammatory chemokine levels can reduce uncertainty of HBeAg-negative chronic hepatitis B phases

HDV genotypes have an impact on pegylated interferon therapy response and long-term liver disease related outcomes

WED-144 - HDV genotypes have an impact on pegylated interferon therapy response and long-term liver disease related outcomes

The rising burden of non-alcoholic fatty liver disease (NAFLD) related HCC: is time running out to contain this silent epidemic?

Aktive Filter

Suchergebnisse filtern